UBS Upgrades Helicos BioSciences (HLCS) to Neutral

March 19, 2008 7:24 AM EDT

UBS upgrades Helicos BioSciences (Nasdaq: HLCS) from Sell to Neutral.

Helicos BioSciences Corporation is a life sciences company developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.


Related Categories

Upgrades

Stocks Mentioned

HLCS 1.38

-0.38 -21.59%
Volume: 3,767,762
Track HLCS


Related Entities


Add Your Comment